IART analyst estimates
Integra LifeSciences (IART) analyst ratings, the average price target and its range, and every firm's latest call.
IART analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 27, 2026 | UBS | Integra LifeSciences price target lowered to $14 from $19 at UBS | $14.00 |
| Oct 23, 2026 | Truist Financial | Integra LifeSciences price target lowered to $13 from $15 at Truist | $13.00 |
| Oct 22, 2026 | Wells Fargo | Integra LifeSciences price target lowered to $13 from $15 at Wells Fargo | $13.00 |
| Oct 22, 2026 | BMO Capital | Integra LifeSciences price target lowered to $14 from $15 at BMO Capital | $14.00 |
| Oct 3, 2026 | Wells Fargo | Integra LifeSciences price target lowered to $15 from $18 at Wells Fargo | $15.00 |
| Jul 28, 2026 | UBS | Integra LifeSciences initiated with a Neutral at UBS | $19.00 |
| Jul 16, 2026 | Truist Financial | Integra LifeSciences price target raised to $19 from $14 at Truist | $19.00 |
| Jul 8, 2026 | BMO Capital | BMO starts 'show-me story' Integra LifeSciences with a Market Perform | $19.00 |
| Jun 18, 2026 | Argus Research | Integra LifeSciences upgraded to Buy from Hold at Argus | $25.00 |
| Apr 15, 2026 | Truist Financial | Integra LifeSciences price target lowered to $12 from $13 at Truist | $12.00 |
| Oct 15, 2025 | Truist Financial | Integra LifeSciences price target raised to $15 from $13 at Truist | $15.00 |
| Oct 7, 2024 | BTIG | BTIG Upgrades Integra LifeSciences (IART) to Neutral | $20.00 |
| Jul 30, 2024 | Citigroup | Citi Downgrades Integra LifeSciences (IART) to Sell | $23.00 |
| Jul 30, 2024 | Truist Financial | Integra LifeSciences price target lowered to $26 from $32 at Truist | $26.00 |
| Jul 29, 2024 | BTIG | Integra LifeSciences downgraded to Sell from Neutral at BTIG | $22.00 |
- 8 firms rate IART: 1 buy, 6 hold, 1 sell.
- The average price target is $15.80 from 5 analysts, from $13.00 to $25.00.
Updated 2026-11-03 12:33 UTC